Medications and Pregnancy Rheumatoid Arthritis

Information for women and men with rheumatoid arthritis thinking about starting a family

Many people with Rheumatoid Arthritis (RA) may wish to have children. If this is you, please discuss this with your rheumatology



team before you try to fall pregnant.

With careful treatment, most people with RA can have healthy pregnancies and healthy babies. Well-controlled RA improves the chance of healthy babies.

Effects of RA on Pregnancy

- Women with RA may take longer to get pregnant.
- It is uncertain whether there are increased miscarriages (pregnancy loss) in women with RA.
- Women with RA are more likely to have smaller babies, premature babies (born too early) and caesarean sections.
- Having good control of your rheumatoid arthritis pre-pregnancy can help with reducing these risks.

Effects of Pregnancy on RA

- RA usually improves during pregnancy.
- However, up to 1 in 5 women with RA may worsen in pregnancy.
- There is an increased risk of flare following childbirth (post-partum), so having a flare plan and an appointment with your rheumatologist post-partum is recommended.

Good control of RA before you fall pregnant will give the best chance of falling pregnant, having a healthy pregnancy and a healthy baby.

Some very effective RA medications can be safely taken during pregnancy. However, some RA medications should not be taken if planning a pregnancy so please talk with your rheumatology team.

Labels and Categories

- There is confusion with Australian government labelling of which medications are safe in pregnancy.
- Please note some of the historical labels

and categories of rheumatology medicines have not been updated by relevant bodies. Always check with your obstetrician, rheumatologist and treating doctors to see which medicines are safe to continue in pregnancy.

Medications in Pregnancy Pain management

- Painkillers such as paracetamol and tramadol as well as nerve pain medicines (e.g. amitriptyline) can be used if needed.
- Morphine-type medications (narcotics) used at high doses close to the birth may be harmful to the baby.
- Anti-inflammatories (NSAIDs) should be avoided in pregnancy unless under medical supervision.
- Some NSAIDs (e.g. ibuprofen) can be safely used in breastfeeding; check with your rheumatologist for more information.

Corticosteroid use e.g. prednisone/prednisolone

- Risks to mothers include:
 - High blood pressure, high sugar levels during pregnancy (gestational diabetes), bone thinning and infection
- Risks to babies include:
 - Prematurity (born too early), low birth weight, premature rupture of membranes and low sugar levels (neonatal hypoglycaemia).
- Because of the above risks, corticosteroids should only be used when other medications for RA are ineffective or cannot be used.
- Low doses (e.g. 5-7.5mg per day) can be used if the benefits outweigh the risk. If used, the dose should be as low as possible.
- It can be taken whilst breastfeeding.
- In men, use is not linked with infertility or harm to the baby.

Disease Modifying Anti Rheumatic Drugs (DMARDs)

Hydroxychloroquine (HCQ)

- Women who wish to become pregnant can use this medication.
- It can be continued during pregnancy at doses of up to 400 mg/day. Higher doses may be considered if the benefits outweigh the risks.
- HCQ can be taken whilst breastfeeding.
- There is no information in men, but it is likely to be safe.





Sulfasalazine (SSZ)

- Women who wish to become pregnant can use this medication. Folic acid supplementation of 2-5mg a day should commence at least 1 month prior to pregnancy planning and continue throughout pregnancy.
- It can be continued during pregnancy.

• SSZ can be taken whilst breastfeeding. As SSZ can cause reduced sperm movement, it should be stopped after 12 months of unsuccessfully trying to father a child.

Tumour Necrosis Factor Inhibitors (TNFi) eg adalimumab, etanercept, golimumab

- Women who wish to become pregnant can use these medications.
- Check with your rheumatologist for the latest recommendations.
- If you need to continue a TNFi in the third trimester, please discuss this with your rheumatologist and/or obstetric physician, and paediatrician.
- The rotavirus vaccine can be given to babies of mothers who have continued TNFis during pregnancy and in the first 6 months of life.
- TNFi can be taken whilst breastfeeding.
- TNFi use in men (paternal exposure) is safe.

Non-TNFi biological DMARDs eg abatacept, rituximab, tocilizumab

- Due to limited information, it is currently recommended to avoid these medications during pregnancy.
- If an unplanned pregnancy occurs, you should see a specialist in the field to discuss the pregnancy.
- Breastfeeding information is limited, but the amount in milk is likely to be very low, and it is probably destroyed in the baby's gut.
- Information is limited but use in men is likely to be safe.

Janus Kinase Inhibitors (JAKi) eg baricitinib, tofacitinib, upadacitinib

- Due to limited information, it is currently recommended to avoid these medications in pregnancy.
- If an unplanned pregnancy occurs, the medication should be stopped and you should see a specialist in the field
- Breastfeeding is not recommended whilst on these medications.
- Based on limited evidence, JAKi are likely to be safe for men planning to father a child.

DMARDs that should be AVOIDED during pregnancy

Methotrexate (MTX)

- This medication can harm the baby.
- It should be stopped 3 months before trying to become pregnant.
- If an unplanned pregnancy occurs, MTX should be stopped immediately, 5 mg folic acid daily started and a specialist in the field should be seen
- Avoid use if breastfeeding.
- MTX (up to 25mg/week) use in men is safe.

Leflunomide (LEF)

- LEF is not recommended for use in pregnancy.
- It should be stopped 2 years before trying to fall pregnant or it is recommended to give a medication (cholestyramine) to washout the LEF.
- If an unplanned pregnancy occurs, LEF should be stopped immediately, cholestyramine washout should be started and a specialist in the field should be seen.
- Avoid use if breastfeeding.
- Leflunomide use in men is safe.

Remember with careful medical and obstetric management, most patients with RA can have successful pregnancies. If you have any

questions, please ask your rheumatology team. The American College of Rheumatology states that women with a low-risk profile should include regular three-month visits to the rheumatologist, as a precaution. Those with a high-risk profile should be managed by a medical and obstetric team with experience in high-risk pregnancies.

More detailed information can be found at:

- Arthritis Australia: <u>https://arthritisaustralia.com.au/managi</u> <u>ng-arthritis/living-with-</u> <u>arthritis/pregnancy/</u>
- American College of Rheumatology Website:<u>https://www.rheumatology.org/</u> <u>I-Am-A/Patient-Caregiver/Diseases-</u> <u>Conditions/Living-Well-with-</u> <u>Rheumatic-Disease/Pregnancy-</u> <u>Rheumatic-Disease</u>
- The Royal Women's Pregnancy and Breastfeeding Medicines Guide <u>Medicines | PBMG</u>
- MotherSafe https://www.seslhd.health.nsw.gov.au/r oyal-hospital-for-women/servicesclinics/directory/mothersafe

Your GP or other members of your care team may find the following ARA resource helpful:

<u>Prescribers Information on Medications for</u> <u>Rheumatic Diseases in Pregnancy</u>





This Information Sheet has been prepared using materials obtained from various sources which have been reviewed by the Australian Rheumatology Association (ARA). It contains general information only and does not contain a complete or definitive statement of all possible uses, actions, precautions, side effects or interactions of the medicines referenced. This information is not intended as medical advice for individual conditions nor for making an individual assessment of the risks and benefits of taking a particular medicine. Decisions regarding the assessment and treatment of patients are the sole responsibility of the treating medical professional, exercising their own clinical judgment and taking into account all of the circumstances and the medical history of the individual patient.

ARA has used all reasonable endeavours to ensure the information on which this Information Sheet is based is accurate and up to date. However, the ARA accepts no responsibility or liability for the accuracy, currency, reliability and/or completeness of the information contained in this Information Sheet. To the maximum extent permitted by law, the ARA expressly disclaims any liability for any injury, loss, harm or damage arising from or in connection with use of and reliance on the information contained in this Information Sheet.

This information sheet is copyright and may be reproduced in its entirety but may not be altered without prior written permission from the ARA.

Please consider the environment before printing this resource.



